Sari H. Pakkanen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sari H. Pakkanen has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Anu Kantele
Meilahti Vaccine Research Center MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
24 shared publications Jussi M. Kantele
Occupational Health and Environmental Medicine, University of Turku, Turku, Finland
8 shared publications- Tinja Lääveri
Aalto University, Department of Computer Science, Espoo, Finland
5 shared publications Anu Kantele
Inflammation Center, Department of Infectious diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 shared publicationsJuha Kirveskari
Department of Bacteriology, Helsinki University Hospital Laboratory, Helsinki, Finland
4 shared publicationsTinja Lääveri
Inflammation Center, Department of Infectious diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
4 shared publications
Latest Publications
- Open Access
- 7 December 2023
- Published by Elsevier in New Microbes and New Infections
- Vol. 56, 101209
Long COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study
- 7 December 2023
- Published by Elsevier in New Microbes and New Infections
- Vol. 56, 101209
Open AccessLong COVID-associated symptoms prevalent in both SARS-CoV-2 positive and negative individuals: A prospective follow-up study
- Open Access
Rapid homogeneous assay for detecting antibodies against SARS-CoV-2
Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past the initial phase of infection and will help to examine possible vaccine responses. The major targets of human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (S) and nucleocapsid protein (N). We have developed a rapid homogenous approach for antibody detection termed LFRET (protein L-based time-resolved Förster resonance energy transfer immunoassay). In LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal generation. We set up LFRET assays for antibodies against S and N and evaluated their diagnostic performance using a panel of 77 serum/plasma samples from 44 individuals with COVID-19 and 52 negative controls. Moreover, using a previously described S construct and a novel N construct, we set up enzyme linked immunosorbent assays (ELISAs) for antibodies against SARS-CoV-2 S and N. We then compared the LFRET assays with these enzyme immunoassays and with a SARS-CoV-2 microneutralization test (MNT). We found the LFRET assays to parallel ELISAs in sensitivity (90-95% vs. 90-100%) and specificity (100% vs. 94-100%). In identifying individuals with or without a detectable neutralizing antibody response, LFRET outperformed ELISA in specificity (91-96% vs. 82-87%), while demonstrating an equal sensitivity (98%). In conclusion, this study demonstrates the applicability of LFRET, a 10-minute ‘mix and read’ assay, to detection of SARS-CoV-2 antibodies.
Open AccessRapid homogeneous assay for detecting antibodies against SARS-CoV-2
Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past the initial phase of infection and will help to examine possible vaccine responses. The major targets of human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (S) and nucleocapsid protein (N). We have developed a rapid homogenous approach for antibody detection termed LFRET (protein L-based time-resolved Förster resonance energy transfer immunoassay). In LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal generation. We set up LFRET assays for antibodies against S and N and evaluated their diagnostic performance using a panel of 77 serum/plasma samples from 44 individuals with COVID-19 and 52 negative controls. Moreover, using a previously described S construct and a novel N construct, we set up enzyme linked immunosorbent assays (ELISAs) for antibodies against SARS-CoV-2 S and N. We then compared the LFRET assays with these enzyme immunoassays and with a SARS-CoV-2 microneutralization test (MNT). We found the LFRET assays to parallel ELISAs in sensitivity (90-95% vs. 90-100%) and specificity (100% vs. 94-100%). In identifying individuals with or without a detectable neutralizing antibody response, LFRET outperformed ELISA in specificity (91-96% vs. 82-87%), while demonstrating an equal sensitivity (98%). In conclusion, this study demonstrates the applicability of LFRET, a 10-minute ‘mix and read’ assay, to detection of SARS-CoV-2 antibodies.
- Open Access
- 1 May 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (5) , 605-611
Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic Escherichia coli (DEC)
Objectives Using a prospective research design, we evaluated the association between acquisition of diarrhoeagenic Escherichia coli (DEC) and development of reactive arthritis (ReA) and other reactive musculoskeletal (MSK) symptoms among international travellers. Methods A total of 526 study participants were asked to provide pretravel and post-travel stool samples and fill in questionnaires (pretravel, post-travel and 3-week follow-up). A multiplex quantitative PCR assay was deployed to detect five DEC comprising enteroaggregative E. coli, enteropathogenic E. coli, enterotoxigenic E. coli, enterohaemorrhagic E. coli and enteroinvasive E. coli and Salmonella, Shigella, Campylobacter, Yersinia, and Vibrio cholerae. Multivariate analysis was employed to identify factors predisposing to MSK symptoms. New post-travel MSK symptoms reported by participants with DEC were assessed by phone interviews and, if needed, clinically confirmed. Results From among the total of 224 volunteers who returned all questionnaires and stool specimens, 38 (17.0%) reported MSK symptoms. Multivariate analysis revealed that acquisition of DEC was associated with MSK symptoms (OR 3.9; 95% CI 1.2 to 13.3). Of the 151 with only-DEC, four (2.6%) had ReA, two (1.3%) reactive tendinitis and three (2.0%) reactive arthralgia. ReA was mostly mild, and all patients with ReA were negative for human leucocyte antigen B27. Antibiotic treatment of travellers’ diarrhoea did not prevent development of MSK symptoms. Conclusion A total of 17% of volunteers reported post-travel MSK symptoms. DEC acquisition was associated with an increased risk of developing them, yet the ReA incidence remained low and the clinical picture mild. Antibiotic treatment did not protect against development of MSK symptoms.
- 1 May 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (5) , 605-611
Open AccessReactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic Escherichia coli (DEC)
Objectives Using a prospective research design, we evaluated the association between acquisition of diarrhoeagenic Escherichia coli (DEC) and development of reactive arthritis (ReA) and other reactive musculoskeletal (MSK) symptoms among international travellers. Methods A total of 526 study participants were asked to provide pretravel and post-travel stool samples and fill in questionnaires (pretravel, post-travel and 3-week follow-up). A multiplex quantitative PCR assay was deployed to detect five DEC comprising enteroaggregative E. coli, enteropathogenic E. coli, enterotoxigenic E. coli, enterohaemorrhagic E. coli and enteroinvasive E. coli and Salmonella, Shigella, Campylobacter, Yersinia, and Vibrio cholerae. Multivariate analysis was employed to identify factors predisposing to MSK symptoms. New post-travel MSK symptoms reported by participants with DEC were assessed by phone interviews and, if needed, clinically confirmed. Results From among the total of 224 volunteers who returned all questionnaires and stool specimens, 38 (17.0%) reported MSK symptoms. Multivariate analysis revealed that acquisition of DEC was associated with MSK symptoms (OR 3.9; 95% CI 1.2 to 13.3). Of the 151 with only-DEC, four (2.6%) had ReA, two (1.3%) reactive tendinitis and three (2.0%) reactive arthralgia. ReA was mostly mild, and all patients with ReA were negative for human leucocyte antigen B27. Antibiotic treatment of travellers’ diarrhoea did not prevent development of MSK symptoms. Conclusion A total of 17% of volunteers reported post-travel MSK symptoms. DEC acquisition was associated with an increased risk of developing them, yet the ReA incidence remained low and the clinical picture mild. Antibiotic treatment did not protect against development of MSK symptoms.
- Open Access
Real-time sampling of travelers shows intestinal colonization by multidrug-resistant bacteria to be a dynamic process with multiple transient acquisitions
Background: Antimicrobial resistance (AMR) is highly prevalent in low- and middle-income countries (LMIC). International travel contributes substantially to the global spread of intestinal multidrug-resistant gram-negative (MDR-GN) bacteria. Of the 100 million annual visitors to LMIC, 30–70% become colonized by MDR-GN bacteria. The phenomenon has been well documented, but since sampling has only been conducted after travelers’ return home, data on the actual colonization process are scarce. We aimed to characterize colonization dynamics by exploring stool samples abroad on a daily basis while visiting LMIC. Methods: A group of 20 European volunteers visiting Lao People’s Democratic Republic for three weeks provided daily stool samples and filled in daily questionnaires. Acquisition of extended-spectrum beta-lactamase-producing gram-negative bacteria (ESBL-GN) was examined by selective stool cultures followed by whole-genome sequencing (WGS) of isolates. Results: While colonization rates were 70% at the end of the study, daily sampling revealed that all participants had acquired ESBL-GN at some time point during their overseas stay, the colonization status varying day by day. WGS analysis ascribed the transient pattern of colonization to sequential acquisition of new strains, resulting in a loss of detectable colonization by the initial MDR-GN strains. All but one participant acquired multiple strains (n=2–7). Of the total of 83 unique strains identified (53 E. coli , 10 Klebsiella , 20 other ESBL-GN species), some were shared by as many as four subjects. Conclusions: This is the first study to characterize in real time the dynamics of acquiring MDR-GN during travel. Our data show multiple transient colonization events indicative of constant microbial competition.
Open AccessReal-time sampling of travelers shows intestinal colonization by multidrug-resistant bacteria to be a dynamic process with multiple transient acquisitions
Background: Antimicrobial resistance (AMR) is highly prevalent in low- and middle-income countries (LMIC). International travel contributes substantially to the global spread of intestinal multidrug-resistant gram-negative (MDR-GN) bacteria. Of the 100 million annual visitors to LMIC, 30–70% become colonized by MDR-GN bacteria. The phenomenon has been well documented, but since sampling has only been conducted after travelers’ return home, data on the actual colonization process are scarce. We aimed to characterize colonization dynamics by exploring stool samples abroad on a daily basis while visiting LMIC. Methods: A group of 20 European volunteers visiting Lao People’s Democratic Republic for three weeks provided daily stool samples and filled in daily questionnaires. Acquisition of extended-spectrum beta-lactamase-producing gram-negative bacteria (ESBL-GN) was examined by selective stool cultures followed by whole-genome sequencing (WGS) of isolates. Results: While colonization rates were 70% at the end of the study, daily sampling revealed that all participants had acquired ESBL-GN at some time point during their overseas stay, the colonization status varying day by day. WGS analysis ascribed the transient pattern of colonization to sequential acquisition of new strains, resulting in a loss of detectable colonization by the initial MDR-GN strains. All but one participant acquired multiple strains (n=2–7). Of the total of 83 unique strains identified (53 E. coli , 10 Klebsiella , 20 other ESBL-GN species), some were shared by as many as four subjects. Conclusions: This is the first study to characterize in real time the dynamics of acquiring MDR-GN during travel. Our data show multiple transient colonization events indicative of constant microbial competition.
- Open Access
- 1 January 2019
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 27, 64-71
Stand-by antibiotics encourage unwarranted use of antibiotics for travelers’ diarrhea: A prospective study
- 1 January 2019
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 27, 64-71
Open AccessStand-by antibiotics encourage unwarranted use of antibiotics for travelers’ diarrhea: A prospective study
- Open Access
- 1 August 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (8) , 908.e9-908.e16
A prospective study of travellers' diarrhoea: analysis of pathogen findings by destination in various (sub)tropical regions
- 1 August 2018
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24 (8) , 908.e9-908.e16
Open AccessA prospective study of travellers' diarrhoea: analysis of pathogen findings by destination in various (sub)tropical regions
- 1 July 2018
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 24, 37-43
Travellers' diarrhoea: Impact of TD definition and control group design on study results
- 1 July 2018
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 24, 37-43
Travellers' diarrhoea: Impact of TD definition and control group design on study results
- 1 May 2018
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 23, 49-55
Despite antibiotic treatment of travellers' diarrhoea, pathogens are found in stools from half of travellers at return
- 1 May 2018
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 23, 49-55
Despite antibiotic treatment of travellers' diarrhoea, pathogens are found in stools from half of travellers at return
- 1 April 2018
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 126, 69-75
Circulating pathogen-specific plasmablasts in female patients with upper genital tract infection
- 1 April 2018
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 126, 69-75
Circulating pathogen-specific plasmablasts in female patients with upper genital tract infection
- 27 September 2017
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 86 (4) , 207-215
Specific and Cross‐reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine
Secondary immunization with polysaccharide vaccines may imply a risk of hyporesponsiveness. Despite the wide use of typhoid Vi capsular polysaccharide vaccine, its potential tendency to hyporesponsiveness has been inadequately addressed. While previous studies have explored serum antibody responses, we applied a more sensitive approach, a single‐cell assay for circulating plasmablasts, to compare primary and secondary responses. Twelve subjects received primary and booster doses of the Vi vaccine (Typherix®) at 30‐ to 37‐month intervals. Plasmablasts specific to the Vi or typhoidal O antigens or cross‐reactive with paratyphoid and non‐typhoidal Salmonella strains were identified as antibody‐secreting cells (ASC) with ELISPOT. Before vaccinations, none had plasmablasts specific to the antigens tested. Twelve of 12 subjects showed a Vi‐specific response after primary, but only eight of 12 after booster vaccination. All responded to typhoidal O‐9,12 antigen after both immunizations. The geometric mean of plasmablasts specific to the Vi antigen was 59 (95% CI 24–119) and 1 (0‐54) IgA + IgG + IgM‐ASC/106 peripheral blood mononuclear cell (PBMC) after primary and booster immunizations, respectively, and 20 (9–49) and 56 (29–103) to the O‐9,12 antigen. We detected 1 (0–28) and 17 (6–36) ASC/106 PBMC cross‐reactive with Salmonella Paratyphi A; 3 (0–30) and 22 (8–48) with S. Paratyphi B; 3 (0–29) and 18 (7–47) with S. Paratyphi C; 19 (10‐34) and 51 (26‐94) with Salmonella Enteritidis; and 1 (0–35) and 23 (9–52) with Salmonella Typhimurium, respectively. One‐third of the vaccinees, although responding to the O‐9,12 antigen, failed to respond to the Vi antigen after booster immunization, suggesting hyporesponsiveness in part of the vaccinees. The findings warrant further investigation.
- 27 September 2017
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 86 (4) , 207-215
Specific and Cross‐reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine
Secondary immunization with polysaccharide vaccines may imply a risk of hyporesponsiveness. Despite the wide use of typhoid Vi capsular polysaccharide vaccine, its potential tendency to hyporesponsiveness has been inadequately addressed. While previous studies have explored serum antibody responses, we applied a more sensitive approach, a single‐cell assay for circulating plasmablasts, to compare primary and secondary responses. Twelve subjects received primary and booster doses of the Vi vaccine (Typherix®) at 30‐ to 37‐month intervals. Plasmablasts specific to the Vi or typhoidal O antigens or cross‐reactive with paratyphoid and non‐typhoidal Salmonella strains were identified as antibody‐secreting cells (ASC) with ELISPOT. Before vaccinations, none had plasmablasts specific to the antigens tested. Twelve of 12 subjects showed a Vi‐specific response after primary, but only eight of 12 after booster vaccination. All responded to typhoidal O‐9,12 antigen after both immunizations. The geometric mean of plasmablasts specific to the Vi antigen was 59 (95% CI 24–119) and 1 (0‐54) IgA + IgG + IgM‐ASC/106 peripheral blood mononuclear cell (PBMC) after primary and booster immunizations, respectively, and 20 (9–49) and 56 (29–103) to the O‐9,12 antigen. We detected 1 (0–28) and 17 (6–36) ASC/106 PBMC cross‐reactive with Salmonella Paratyphi A; 3 (0–30) and 22 (8–48) with S. Paratyphi B; 3 (0–29) and 18 (7–47) with S. Paratyphi C; 19 (10‐34) and 51 (26‐94) with Salmonella Enteritidis; and 1 (0–35) and 23 (9–52) with Salmonella Typhimurium, respectively. One‐third of the vaccinees, although responding to the O‐9,12 antigen, failed to respond to the Vi antigen after booster immunization, suggesting hyporesponsiveness in part of the vaccinees. The findings warrant further investigation.